

A detailed 3D rendering of red blood cells in a blood vessel. The cells are shown in various sizes and orientations, with a prominent one in the foreground on the right. The background is a warm, reddish-orange glow, suggesting the interior of a vessel.

Interim Report January to June 2015

Overview of Key Financial Figures

		04/01/- 06/30/2015	04/01/- 06/30/2014	01/01/- 06/30/2015	01/01/- 06/30/2014
Profit/Loss					
Total operating revenue	EUR k	3,664	3,131	7,091	6,650
Revenues	EUR k	3,349	2,877	6,418	6,090
Gross profit	EUR k	1,954	1,624	3,699	3,488
EBITDA	EUR k	505	231	1,117	819
EBITDA margin	%	15.1	8.0	17.4	13.4
EBIT	EUR k	239	-16	578	294
Period result	EUR k	133	-90	362	114
Earnings per share	EUR	0.04	-0.02	0.13	0.05
Balance Sheet/Cash flow				06/30/2015	06/30/2014
Total assets	EUR k			38,269	35,372
Equity	EUR k			22,488	21,406
Equity ratio	%			58.8	60.5
Liquid funds	EUR k			2,093	3,314
Capital expenditures ¹	EUR k	264	117	808	239
Depreciation ¹	EUR k	266	247	539	525
Cash flow from operating activities	EUR k	159	-140	1,492	456
Employees					
Employees (as of 30 June)	Number			105	106
Personnel expenditures	EUR k			2,323	2,338

¹ Information for tangible and intangible assets

Content

- To Our Shareholders 2**
 - Letter from the Management Board 2
 - Vita 34 AG Stock 4

- Group Interim Report 6**
 - Group Fundamentals 8
 - Economic Report 11
 - Subsequent Report 15
 - Opportunity and Risk Report 15
 - Prognosis Report 16

- Condensed Consolidated Interim Financial Statement 18**
 - Condensed Consolidated Statement of Income 20
 - Condensed Consolidated Statement of Comprehensive Income 21
 - Condensed Consolidated Statement of Financial Position 22
 - Condensed Consolidated Statement of Changes in Group Equity 24
 - Condensed Consolidated Statement of Cash flows 26

- Notes on the Condensed Consolidated Interim Financial Statement 27**

- Declaration of the Legal Representatives 34**

- Contact Information**

Dear Shareholders,

In the first half-year 2015 we worked consistently on the implementation of our new growth strategy. We were able to achieve important milestones, in particular with regard to strengthening our market leadership, as well as expanding our research activities. The course has been set for sustainable corporate development.

After Vita 34 had signed a purchase agreement at the end of fiscal year 2014 for taking over all of the assets of the Austrian Vivocell company effective January 2, 2015, the assets were fully consolidated in Q1 2015. The Austrian market-leading stem cell bank is now part of the Vita 34 Family. Correspondingly, Vita 34 has bolstered its own position as the largest stem cell bank in the German-speaking countries.

Moreover, we have solidified our position as one of the largest umbilical cord blood banks in Europe: Vita 34 had entered into a cooperative agreement with the Baltic stem cell bank AS "Imunolita" at the beginning of fiscal year 2015, and acquired the majority of voting rights, as well as 35 percent of the equity in the Baltic partner in July of this year. In particular, Imunolita will work closely together with Vita 34, especially in expanding marketing and sales activities in Lithuania, Estonia and Latvia. In addition, Vita 34 acquired the majority of voting rights and 30 percent of the equity in its partner of many years, Bio Save, in July 2015. With this investment, Vita 34 is pursuing the goal of expanding its market share to the Eastern European market. Vita 34 stored the first stem cell units, both from the Baltic countries, as well as from Slovakia, in Q2 2015 in the cryo-tanks in Leipzig, after subsidiary VITA 34 Slovakia, s.r.o. began business operations in Q1 2015. In the reporting period we successfully continued our foreign expansion – apart from Germany, Vita 34 is now active in Europe and globally in 20 countries.

The advances made show in our financial figures. With an increased total operating revenue of EUR 7.1 million (first half-year 2014: EUR 6.7 million) revenues increased from some EUR 6.1 million to EUR 6.4 million in the reporting period. Despite increased administrative expenses in the reporting period associated with the integration of the stem cell units of our Vivocell subsidiary, the earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 1.1 million was higher than the prior year's level (first half year 2014: EUR 0.8 million). The earnings before interest and taxes (EBIT), which nearly doubled to EUR 0.6 million, developed analogously (first half-year 2014: EUR 0.3 million).

We will continue with strength, motivation and passion to pursue our goal of establishing Vita 34 even more strongly as an internationally leading provider of products based on stem cells. In this context our own research, in particular, will play a central role. Vita 34 expanded its research activities in the first half-year of 2015 with new projects, and achieved important project objectives.

With more than 127,000 stem cell units, Vita 34 is indisputably the largest stem cell bank in the German-speaking countries. From our leading market position we will take advantage of every opportunity in fiscal year 2015 and beyond to further strengthen our market leadership, to develop the product portfolio, and to expand our own research activities.

We would like to sincerely thank our shareholders for their trust in Vita 34, and hope that you will continue to accompany us.

Leipzig, July 2015




Dr. André Gerth
CEO



Jörg Ulbrich
CFO

Vita 34 AG Stock

Stock Price Development (January 2, 2015–July 20, 2015)



Stock Price Development


The Vita 34 AG stock is listed in the regulated market (segment: Prime Standard) of the Frankfurt Stock Exchange. The stock started the year on January 2, 2015 with a price of EUR 4.88. The stock hit its low of EUR 4.72 in the reporting period already on January 6, 2015. The further course of the first quarter was characterized by a continuous upward trend, which resulted in the quarter high of EUR 6.05 on March 30, 2015. At the beginning of Q2 the stock price increased significantly and reached its absolute high of EUR 7.29 during the reporting period on April 10, 2015. This was followed by a downward trend in the second half of the first half of the year. On June 30, 2015, on the last day of Q2, the stock was quoted at EUR 5.34, which is equivalent to a market capitalization of EUR 16.2 million. Thus, the stock has achieved an increase of 9.4 percent since the beginning of the fiscal year. In the first half-year 2015 on average some 13,700 Vita 34 shares were traded per day on the Xetra trading platform.

Information and Key Figures on the Shares

Ticker symbol/ Reuters symbol	V3V/ V3VGn.DE
Securities number/ISIN	A0BL84/DE000A0BL849
Initial quotation	03/27/2007
Market segment	Prime Standard
Indices	CDAX, Prime All Share, Technology All Share, DAXsubsector Biotechnology, DAXsector Pharma & Healthcare
Opening/Closing Price	EUR 4.88/EUR 5.34
High/Low	EUR 7.29/EUR 4.72
Number of shares	3,026,500
Free-float as of June 30, 2015	68.0 percent
Market capitalization as of June 30, 2015	EUR 16.2 million
Designated Sponsor	ODDO SEYDLER Bank AG

Shareholder Structure

as of June 30, 2015



Vita 34 AG currently has a high level of free-float at 68.0 percent and has a broad base of shareholders that was expanded in the reporting period. As of June 30, 2015, CEO Dr. André Gerth held 12.7 percent of the shares. The overall portion held by Vita 34 management was 17.5 percent. The portion held by Human Stem Cells Institute OJSC (HSCI), Moscow, was 11.2 percent. Axxion S.A. has held more than 3 percent since March 3, 2015, and as of June 30, 2015 3.3 percent. Landesbank Baden-Württemberg, on the other hand, reduced its shares according to plan over the course of Q1 2015, and sold the remainder of its shares on April 2015.

Investor Relations

The investor relations work at Vita 34 aims to provide an active and transparent dialog with shareholders and stakeholders. In this context, the Management Board participates regularly in capital market conferences, for example, in the first half-year 2015 in the DVFA spring conference in Frankfurt, Main. Dr. André Gerth reported on the operative activities of Vita 34 within the context of the company presentation, and was available to interested investors. Analysts and journalists for one-on-one discussions.

During the reporting period ODDO SEYDLER Bank AG continued to act as Designated Sponsor. In their update on April 28, 2015, the analysts continued with a buy recommendation for the stock and a target price of EUR 7.50.

Additional information on the Vita 34 stock are available for download on the Internet at www.vita34group.com in the "Share" section.

Financial Calendar 2015

July 28, 2015	Annual General Meeting 2015
October 22, 2015	Publishing of the 9-month report 2015

Group Interim Report

Group Fundamentals	8
Business Model	8
Economic Report	11
Overall Economic Environment and Industry-Related Peripheral Conditions	11
Development of Business	11
Revenue and Profit Situation	13
Financial Situation	14
Assets	14
Subsequent Report	15
Opportunity and Risk Report	15
Prognosis Report	16

Group Interim Report

Group Fundamentals

Business Model

Vita 34 developed from being a European pioneer in the field of umbilical cord blood banking to be the second largest umbilical cord blood bank in Europe. Founded in 1997, today Vita 34 has over 127,000 stem cell units and storage capacity for up to 350,000 stem cell units, making it by far the largest stem cell bank in the German-speaking countries. The company is active in two business segments, "Stem Cell Banking" and "Biotechnology," and apart from Germany is represented in the European and global markets in a total of 20 countries via subsidiaries and cooperation partners.

The offering of Vita 34 is targeted towards expecting parents who wish to have the stem cells from the umbilical cord, which are extremely vital directly after birth, preserved for their children as a provision. The stored stem cell units are available to the child over many decades for use, among other things, in therapies for auto-immune diseases, metabolic disorders and brain damage. In regenerative medicine the use of stem cells from umbilical cord blood and tissue also has significant potential for restoring the function of tissue and organs. As a complete provider in the field of "Stem Cell Banking", Vita 34 covers the entire value chain: From collection logistics, to preparation and the long-term storage of umbilical cord blood and tissue, to the proper dispensing of stem cell transplants for medical use.

The fulfillment of legal provisions and guidelines is a high priority in the corporate actions at Vita 34. The German Pharmaceuticals Act (AMG) regulates the production requirements, required personnel and quality management in Germany. More detailed information on this can be found in the "Sustainability" chapter of the Vita 34 AG annual report dated March 26, 2015. This can be found on the Vita 34 website (www.vita34group.com).


Vita 34 is the only private stem cell bank in Germany that can demonstrate a number of medical applications for stem cell preparations stored for one's own use. This gives testimony to the work and performance of Vita 34, which ensures reliable processing and long-term storage with the highest standards of quality and safety.

Apart from practical application, Vita 34 is set apart by research activities and a large number of permits and intensive research activities. For example, in addition to a permit for dispensing umbilical cord blood to one's own child, Vita 34 is the only private stem cell bank to possess:

- Permits from the German Federal Institute for Vaccines and Biomedical Pharmaceuticals (Paul-Ehrlich Institute) for dispensing umbilical cord blood preparations for the therapeutic use in hematological/oncological diseases for siblings, and to help other people in the case of disease in the form of a donation.
- A permit for the collection, processing, cryo-preservation and storage of umbilical cord tissue in Germany, Austria and Switzerland (DACH region), as well as
- The capability and the required permits to provide customers with both the storage of whole blood as well as separated blood.

In order to study the potential medical applications of umbilical cord blood stem cells and develop new cell products, Vita 34 actively participates in applied stem cell research. In addition, Vita 34 cooperates with renowned research institutes and universities throughout Germany. With the storage of different stem cell materials Vita 34 would like to establish quality standards for later use, and to continue to research the functioning of stem cells from umbilical cord blood and tissue. Thus, Vita 34 is creating the potential of achieving quick access to innovative products in the field of stem cells.

Corporate Structure



Corporate Structure


The publicly traded Vita 34 AG company is the parent of the Group: Vita 34 holds 100 percent interests in Novel Pharma, S.L. (Spain), VITA 34 Slovakia, s.r.o. (Slovakia) and VITA 34 Gesellschaft für Zelltransplantate m.b.H. (Austria). In addition, there is a 75.24 percent participation in stellacure GmbH (Germany), as well as an 88 percent participation in Secuvita S.L. (Spain) via Novel Pharma, S.L. (Spain).

Vita 34 on the International Market

Foreign business via subsidiaries and cooperative venture partners is a significant component of company activity. Vita 34 has continuously expanded its activities in the international market in the last few years, and was active in 20 countries apart from Germany in Europe and worldwide as of the end of the reporting period.

Vita 34 provides its European cooperative venture partners with comprehensive service. This encompasses the collection kit developed by Vita 34 and the preparation of the stem cell units for long-term storage in the cryo-tanks in Leipzig. International cooperation partners use the “Vita 34 Bag” collection system developed and patented by Vita 34, which allows decentralized preparation and storage of umbilical cord blood outside of clean rooms, and reduces cost-intensive start-up investments.

International Presence – The Vita 34 Family



Objectives and Strategy

For a sustainable corporate development Vita 34 defined a strategy with three cores: strengthening market leadership, additional product development, and accelerated expansion of research and development. With inorganic growth as well as opening up of new markets, services and product ranges Vita 34 will generate sustainable revenue and earnings development. More detailed information on this can be found in the “Objectives and Strategy” chapter of the Vita 34 AG annual report dated March 26, 2015. This can be found on the Vita 34 website (www.vita34group.com).

Control System and Performance Indicators

The Management Board of Vita 34 uses the following key figures for internal group control of the company: Total operating revenue, earnings before interest, taxes, depreciation and amortization (EBITDA), EBITDA margin, and equity ratio. The development of the control variables as compared with defined targets is reported on an annual basis. More detailed information on this can be found in the “Control System and Performance Indicators” chapter of the Vita 34 AG annual report dated March 26, 2015. This can be found on the Vita 34 website (www.vita34group.com).

Economic Report

Overall Economic Environment and Industry-Related Peripheral Conditions

Vita 34 has continually expanded its activities in international markets, especially the European market, over the last few years via subsidiaries, as well as sales partners and cooperative venture partners. Therefore, the economic environment in Europe and, in particular, in the Vita 34 target markets, has an influence on business activities.

The economic situation in the Eurozone has further stabilized according to the Kiel Institute for the World Economy (IfW), and is generally trending upward. The gross domestic product (GDP) in the Eurozone increased in Q1 2015 by 0.3 percent, following 0.2 and 0.3 percent in the two quarters prior to that. The speed of the recovery, however, will remain moderate for the time being. According to estimates by IfW the GDP in the current year will increase by some 1.5 percent. The experts are predicting an increase of 1.8 percent for 2016. For 2015, IfW expects an increase in GDP in Germany of 1.8 percent. In the coming year the rate of growth should accelerate to 2.1 percent.

An additional indicator for the "Stem Cell Banking" business activities is, the purchasing power of the general populace. The decision for the storage of umbilical cord blood and tissue is significantly dependent upon this. Private consumption of households should remain stable in the current year according to the European Central Bank (ECB) thanks to increasing incomes and low unemployment. Moreover, the low energy prices in the last few months have influenced the disposable income of private households.

Vita 34 offers a private health provision with the storage of umbilical cord blood and tissue in an extremely dynamic environment with a continuously growing state of research. The increasing number of studies, as well as the results of the work of renowned scientists, is an indicator for the medical potential of stem cells from umbilical cord blood and tissue. Currently more than 1,000 clinical studies with

umbilical cord blood and more than approx. 300 with umbilical cord tissue are registered worldwide, dealing with specific areas of application (www.ClinicalTrials.gov). Results from research and development provide a long-term prerequisite for the further development of the core business of Vita 34, since this is how the potential for application variety related to stem cells from umbilical cord grows. Worldwide there is a continuously increasing number of therapeutic applications with stem cells from umbilical cord blood. In all, 30,000 umbilical cord blood transplantations have taken place to date.

Development of Business

During the first half-year of 2015 Vita 34 worked continuously on strengthening and expanding its leading market position in the German-speaking countries and internationally. In concrete terms, the following measures were focused on:

Market Leadership

Europe

Effective January 2, 2015 Vita 34 acquired the assets of Vivocell Biosolutions GmbH & Co KG, Graz. Via an asset deal the market-leading stem-cell bank in Austria became part of the Vita 34 Family, and Vita 34 was correspondingly able to bolster its position as the largest stem cell bank in the German-speaking countries. The plant and equipment of Vivocell were fully consolidated in Q1 2015. Within the scope of the asset deal, apart from the stem cell units, also the required cryo-tanks, storage equipment, nitrogen supply systems as well as the equipment for cryo-preservation and the storage of umbilical cord blood were transferred to Vita 34.

In addition, Vita 34 signed a cooperation agreement in January 2015 with the Lithuanian stem cell bank AS "Imunolita." With this market entry into the Baltic region, Vita 34 is consistently pursuing its foreign expansion. Vita 34 is now active in 20 countries apart from Germany on the European and global markets. The agreement provides that Imunolita, founded in 2007, will

independently assume the responsibility for marketing and sales for the storage of umbilical cord blood in Lithuania, Estonia and Latvia. Imunolita is using the collection pack developed by Vita 34 and offers parents the storage of umbilical cord blood in Germany.

Our subsidiary VITA 34 Slovakia, s.r.o., commenced business operating in Q1 2015. The prerequisite for starting business was a permit for the collection, distribution and export of umbilical cord blood, which was granted by the pertinent authorities in the first quarter. In Q2 2015 Vita 34 already stored the first stem cell units, both from the Baltic region, as well as from Slovakia, at its headquarters in Leipzig.

Worldwide

The establishment of stem cell banks in the important growth markets of Asia and Latin America, is an important part of our corporate strategy. During the reporting period Vita 34 was successful in advancing the activities beyond the borders of Europe in Vietnam and China, thereby achieving an important milestone: After Vita 34 had signed a „letter of intent“ (LOI) with the private clinic Van Hanh Hospital in Ho Chi Minh City, Vietnam, in Q4 2014 already, a cooperative agreement was closed in April 2015. A stem cell center will be established, in which the potential of stem cells for medical applications will be studied and applied.

In addition, the establishment of the first official stem cell bank according to European standards in Hanoi, Vietnam, will continue to be implemented. Vita 34 is significantly supporting the establishment of the stem cell bank, and is providing technical expertise within the context of the cooperation with the partners in Vietnam. Vita 34 is also taking on the training of the local employees. Thus, the processing and storage of umbilical cord blood will be ensured according to the GMP quality standards (Good Manufacturing Practice) used by Vita 34 and binding in Germany for pharmaceutical production.

In April a “letter of intent“ (LOI) for cooperation in the building and commissioning of an umbilical cord blood bank in Yinchuan, China, was signed with representatives from AVIC Biology. Here, Vita 34 will be responsible for the technological planning and training of employees. Within the scope of the cooperation, collaboration in the areas of quality assurance, research and development, and ongoing training are planned.

Expansion of R&D

The expansion of research initiatives is a significant part of the growth strategy outlined by Vita 34. Via successful research, Vita 34 can open up the potential of establishing new products based on stem cells in the field of regenerative medicine. Overall, the research activities at Vita 34 this year and in the coming two fiscal years are being supported by EU, German Federal and State grants amounting to nearly EUR 1.6 million. This is significantly topping up the research budget at Vita 34 and the effect will be multiplied from using our own funds. Vita 34 expanded its research activities in the first half-year of 2015 with new projects, and achieved important project objectives:

Beginning in fiscal year 2014 Vita 34 started a development project on the cryo-preservation of autologous fatty tissue in its own research laboratory in cooperation with domestic partners. Within the scope of this project Vita 34 was able to isolate cells capable of division in fatty tissue, among them mesenchymal stem cells, as well. Thus, an important milestone on the way to developing a process for cryo-preservation of the stem cells contained in fatty tissue has been reached. In order to open up additional sources for the collection of mesenchymal stem cells besides umbilical cord and fatty tissue, Vita 34 started a further research project at the beginning of the year. The goal is the evaluation of different stem cell sources. To this end, mesenchymal stem cells will be isolated from the tissue and studied for their ability to differentiate.

Vita 34 was able to make decisive discoveries in an additional research project together with the University of Leipzig. The objective was to determine how a mesenchymal stem cell preparation from the umbilical cord needs to be prepared, such that it can be employed most effectively for preventing or treating GvHD (Graft vs Host Disease). To this end, fundamental parameters such as the type of transplantation, stem cell concentration and the ideal treatment time frame were determined.

In addition, Vita 34 is currently testing the effect of plant stem cells on the vitality and growth of human stem cells from umbilical cord blood and tissue.

Revenue and Profit Situation

In the reporting period **total operating revenue** increased to EUR 7.1 million following EUR 6.7 million in the prior year's reference period. Here, the **sales revenues** of the first half-year 2015 increased by 5.4 percent to EUR 6.4 million (first half year 2014: EUR 6.1 million). Of this, Vita 34 posted revenues of EUR 3.3 million in Q2 2015, following EUR 2.9 million in the prior year's quarter. According to business segment, in the first six months of 2015 some EUR 6.2 million was attributable to the Stem Cell Banking segment (first half-year 2014: EUR 5.8 million) and some EUR 0.2 million to the Biotechnology business segment (first half-year 2014: 0.3 million).

In Q2 2015 the **cost of sales** was EUR 1.4 million, following EUR 1.3 million in the prior year's reference period. Based on the increase in new deposits and the associated costs for preparation, the cost of sales increased in the first half-year to EUR 2.7 million (first half-year 2014: EUR 2.6 million). The **gross profit on sales** in Q2 2015 amounted to EUR 2.0 million (Q2 2014: EUR 1.6 million). This is equivalent to a gross margin of 58.3 percent, as compared with 56.4 percent in the reference period of the prior year. In the first half-year of 2015 the gross profit totaled EUR 3.7 million, following EUR 3.5 million in the 2014 reporting period. This is equivalent to a gross margin of 57.6 percent (first half-year 2014: 57.3 percent).

The netted **other operating expenses and income** in Q2 2015 were EUR 0.3 million (Q2 2014: EUR 0.2 million). The other operating expenses and income increased as compared to the first six months of 2014 from EUR 0.5 million to EUR 0.7 million in the reporting period. The increase was the result of income from the valuation of the assets acquired from Vivovell Biosolutions GmbH & Co KG.

The **marketing and selling expenses** in Q2 2015 were EUR 1.2 million (Q2 2014: EUR 1.1 million). In all, the marketing and selling expenses of some EUR 2.2 million in the first half-year 2015 were below the prior year's value (Q1 2014: EUR 2.3 million) due to a shift in the timing of activities. **Administrative Costs** in Q2 2015 were EUR 0.8 million (Q2 2014: EUR 0.7 million). The slight increase is mainly attributable to the integration of the stem cell units transferred to the Vita 34 Group from Vivocell. Overall, administrative costs in the reporting period were EUR 1.6 million following EUR 1.4 million in the comparative period of the prior year.

Correspondingly, the **earnings before interest, taxes, depreciation and amortization (EBITDA)** of EUR 1.1 million in the first half-year of 2015 were higher than the value of EUR 0.8 million in the prior year's period. The **earnings before interest and taxes (EBIT)** increased to EUR 0.6 million in the reporting period (first half-year 2014: EUR 0.3 million). With **earnings before tax (EBT)** in the amount of EUR 0.6 million (first half-year 2014: EUR 0.3 million) **income tax expense** remained nearly unchanged at EUR 0.2 million (first half-year 2014: EUR 0.2 million).

The **period result** increased in the first half-year 2015 to EUR 0.4 million (first half-year 2014: EUR 0.1 million). This resulted in **earnings per share** of EUR 0.13 in the reporting period based on an average number of issued shares of 3,026,500, following EUR 0.05 in the 2014 reference period.

Financial Situation

Based on a **period result before** income tax in the amount of some EUR 0.6 million in the first half-year 2015 (first half-year 2014: EUR 0.3 million), with some EUR 0.5 million the lion's share of cash adjustments were attributable to scheduled depreciation (first half-year 2014: EUR 0.5 million). Additional adjustments in the amount of EUR -0.2 million were attributable to non-cash expenses/income (first half-year 2014: EUR +21k).

Vita 34 posted an inflow of EUR 0.8 million in net current assets in the reporting period, following an outflow in the first half-year 2014 of EUR 0.4 million. This change can be attributed, in particular, to the reduction in receivables and other assets in the amount of EUR 0.8 million (first half-year 2014: EUR 0.4 million). This mainly pertained to a receivable owed by a commercial customer of the company. Thus, the **cash flow from operating activities** in the reporting period of EUR 1.5 million was higher than the prior year's value of EUR 0.5 million.

In the first half-year of 2015 Vita 34 invested a total of EUR 0.8 million in intangible assets and plant and equipment, thus more than the EUR 0.2 million in the comparable period the prior year. In addition, during the reporting period long-term investments in financial assets of EUR 3.1 were made (first half-year 2014: EUR 0). Correspondingly, the **cash flow from investment activity** of EUR -3.9 million was significantly lower than the prior year's value of EUR -0.2 million. The **cash flow from financing activity** was EUR 0.8 million in the reporting period, following EUR 0.2 million in the first half-year of 2014. This change is attributable to taking out a loan in conjunction with the asset deal for implementing the growth strategy in Q1 2015.

As of June 30, 2015 Vita 34 had **cash and cash equivalents** amounting to some EUR 2.1 million (June 30, 2014: EUR 3.3 million). This reduction is the result, among other things, of the investment in long-term financial assets. The cash and cash equivalents form a solid basis for further growth.

Assets


The **balance sheet total** increased from EUR 37.1 million as of December 31, 2014 to EUR 38.3 million. On the asset side of the balance sheet the **non-current assets** were EUR 30.1 million (December 31, 2014: EUR 27.1 million). This increase is mainly attributable to the increase in other financial assets in the amount of EUR 3.2 million (first half-year 2014: EUR 0.6 million). In particular, the non-current assets contain **goodwill** of EUR 13.9 million, which remained unchanged as compared with December 31, 2014. This is comprised of the goodwill of Vita 34 AG, the Spanish subsidiary Secuvita S.L., and the Biotechnology business segment.

Current assets as of June 30, 2015 were EUR 8.1 million, (December 31, 2014: EUR 10.0 million). Accordingly, **cash and cash equivalents** as of June 30, 2015 decreased to EUR 2.1 million down from EUR 3.7 million as of December 31, 2014. This is attributable to non-current asset investments made.

On the liabilities side of the balance sheet, **equity** as of the closing date June 30, 2015 was EUR 22.5 million due to increased retained earnings and, thus, over the 2014 year end level of EUR 22.2 million. This resulted in an equity ratio as of the closing date of the reporting period of 58.8 percent as compared with 59.8 percent as of December 31, 2014.

The **non-current liabilities and deferred income** were EUR 12.2 million as of June 30, 2015, following EUR 11.1 million at the end of fiscal year 2014. This development was mainly based on an increase in interest-bearing loans to EUR 1.0 million as of June 30, 2015 (December 31, 2014: EUR 0.2 million). **Current liabilities and deferred income** decreased from EUR 3.8 million as of year's end 2014 to EUR 3.6 million as of June 30, 2015. This decline resulted, in particular, from lower trade liabilities of some EUR 0.6 million as of the closing date June 30, 2015 (December 31, 2014: EUR 1.1 million). **Deferred Income** totaled EUR 10.1 million as of June 30, 2015 (December 31, 2014: EUR 9.9 million). This contains the storage fees that are collected from customers one time in advance, and are dissolved in linear fashion over the agreed storage period.

Balance Sheet



Subsequent Report

At the beginning of Q3 Vita 34 acquired the majority of voting rights and 30 percent of the equity in its partner of many years, Bio Save d.o.o. Thus, Bio Save will be fully integrated into the Group, and Vita 34 will participate fully in the success of Bio Save. There has been a successful cooperative sales effort between Vita 34 and Bio Save since April 2012, which in the meantime has been extended to cover many countries in the Balkans.

In addition, Vita 34 also acquired the majority of voting rights, as well as 35 percent of the business interest in its cooperative venture partner Kamieninių laštelių bankas UAB (AS „Imunolita“), Lithuania. Based on the agreement signed by both parties, Imunolita will be integrated into the Vita 34 Group, which will have an influence on the operative business of the Lithuanian market leader.

Following the closing of the reporting period, no further significant events have occurred that would have had a special significance for or a substantial effect on the picture of the asset, financial and profit situation of the Group portrayed by this interim report.

Opportunity and Risk Report

As compared with the opportunities and risks presented in the 2014 annual report, there have been no significant changes in the reporting period. More information on the special risks and opportunities of Vita 34 AG can be found in the “Internal Controlling and Risk Management System”, “Company Risks” and “Opportunities for Future Development” chapters of the Vita 34 AG annual report of March 26, 2015. This can be found on the Vita 34 website (www.vita34group.com).

Prognosis Report

Outlook

In our outlook report we deal, to the extent possible, with the expected future development of Vita 34 AG in the current fiscal year 2015.

In the reporting period Vita 34 earned total operating revenues of EUR 7.1 million (first half-year 2104: 6.7 million). The earnings before interest, taxes, depreciation and amortization (EBITDA) rose to EUR 1.1 million (first half-year 2014: EUR 0.8 million). Thus, we can look back on an altogether pleasing first half-year 2015, which was in accordance with our expectations for the year as a whole. We, therefore, correspondingly confirm the prognosis for fiscal year 2015. Due to the ongoing tense economic situation in Europe and the necessary expenditures for implementing our corporate strategy decided on at the end of 2014, Vita 34 sees in this prognosis total operating revenues and an operating result (EBITDA) at the 2014 level.

In the first half of 2015 we placed our main emphasis on bolstering our market leadership, as well as in expanding our own research activities. In taking over the Austrian Vivocell company we have underscored our position as a market dominating umbilical cord blood bank in the German-speaking countries. Additional synergetic effects will be realized in the marketing and sales areas, as well as in the production and administration areas, and in advancing sales activities in the German-speaking region. In the wake of the cooperative agreement with the Baltic stem cell bank AS "Imunolita" and the corresponding acquisition of business shares; we expect the first revenue contributions from the Baltic region in the course of the

second half of 2015. With the investment into our partner of many years Bio Save we expect to be able to expand our market share to the Eastern European market. The commencement of operative business activities at our Slovakian subsidiary VITA 34 Slovakia, s.r.o., is an additional step in realizing additional revenue and income. It is our endeavor in the further course of the current fiscal year to consistently pursue geographic expansion, in order to participate in the potential of as many markets as possible.

Apart from international expansion, we are pursuing the goal of further extending the value chain via the development and introduction of new products for pharmaceutical manufacture, thereby achieving a significant market position. Correspondingly, we have intensified our research activities in the reporting period. We have achieved an important milestone on the way to developing a process for cryo-preservation of the stem cells contained in fatty tissue already with the isolation of divisible cells in fatty tissue. In the current year we will consistently promote this research product.

We are convinced that by implementing the growth strategy we can positively shape the business development of Vita 34 in the long-term. The basis for revenue and profit growth is market penetration and opening, the development of the product range, and expansion of our research initiatives. The progressing developments in the field of regenerative medicine document the good chances of success for further development of the company in the medium term. Therefore, we will continue to pursue the objective of further extending our market position as a specialist for the cryo-preservation of biological materials.

Forward-Looking Statements

This interim report contains forward-looking prognoses. These statements are based on the current level of information available to Vita 34 at the point the report was drafted. Such forward-looking statements are subject, however, to risks and uncertainties. If the assumptions taken as a basis should not transpire or additional opportunities/risks arise, the actual events could deviate strongly from the estimates rendered. Vita 34 can assume no responsibility for this information.

Leipzig, July 2015

The Vita 34 AG Management Board



Dr. André Gerth
CEO



Jörg Ulbrich
CFO

Condensed Consolidated Interim Financial Statement

and Notes

Condensed Consolidated Interim Financial Statement	18
Condensed Consolidated Statement of Income	20
Condensed Consolidated Statement of Comprehensive Income	21
Condensed Consolidated Statement of Financial Position	22
Condensed Consolidated Statement of Changes in Group Equity	24
Condensed Consolidated Statement of Cash flows	26
Notes on the Condensed Consolidated Interim Financial Statement	27

Condensed Consolidated Statement of Income

EUR k	Note	04/01- 06/30/2015	04/01- 06/30/2014	01/01- 06/30/2015	01/01- 06/30/2014
Revenue		3,349	2,877	6,418	6,090
Cost of sales		-1,395	-1,253	-2,719	-2,602
Gross profit on sales		1,954	1,624	3,699	3,488
Other operating income		300	236	676	511
Marketing and selling expenses		-1,188	-1,110	-2,187	-2,243
Administrative expenses		-798	-741	-1,569	-1,428
Other operating expenses		-29	-25	-41	-34
Net operating profit/loss (EBIT)		239	-16	578	294
Finance revenue		13	7	61	57
Finance costs		-18	-16	-35	-31
Earnings before taxes		234	-25	604	320
Income tax expense/income	6	-101	-65	-242	-206
Period result		133	-90	362	114
Period result attributable to					
Owners of the parent		133	-60	391	166
Non-controlling interests		0	-30	-29	-52
Earnings per share (EUR)					
Basic and diluted, for profit or loss for the year attributable to ordinary equity holders of the parent (EUR)		0.04	-0.02	0.13	0.05

Condensed Consolidated Statement of Comprehensive Income

EUR k	Note	04/01- 06/30/2015	04/01- 06/30/2014	01/01- 06/30/2015	01/01- 06/30/2014
Period result		133	-90	362	114
Net profit/ loss from available-for-sale financial assets		-49	0	-49	0
Income tax effect		15	0	15	0
Other result to be reclassified into consolidated statement of income in subsequent periods		-34	0	-34	0
Comprehensive income after tax		99	-90	328	114
Attribution of comprehensive income to					
Owners of the parent company		99	-60	357	166
Shares of other shareholders		0	-30	-29	-52

Condensed Consolidated Statement of Financial Position (Equity & Liabilities)

EUR k	Note	06/30/2015	12/31/2014
Equity			
Issued capital		3,027	3,027
Capital reserves		18,213	18,213
Revenue reserves		1,781	1,390
Other reserves		-156	-122
Treasury shares		-436	-436
Non-controlling interests		59	88
		22,488	22,160
Non-current liabilities and deferred income			
Interest-bearing loans		998	164
Silent partners' interests		940	940
Deferred income taxes		716	463
Deferred grants		1,075	1,121
Deferred income		8,498	8,367
		12,227	11,055
Current liabilities and deferred income			
Trade payables		975	696
Provisions		61	103
Income tax payable		152	239
Interest-bearing loans		13	87
Deferred grants		94	94
Other liabilities		617	1,080
Deferred income		1,642	1,542
		3,554	3,841
		38,269	37,056

Condensed Consolidated Statement of Changes in Group Equity

EUR k	Equity attributable to the			
	Issued capital	Capital reserves	Revenue reserve	Reserves for available-for-sale financial assets
Note				
Balance as of January 1, 2014	3,027	23,950	-5,447	0
Period result	0	0	166	0
Balance as of June 30, 2014	3,027	23,950	-5,281	0
Balance as of January 1, 2015	3,027	18,213	1,390	0
Period result	0	0	391	0
Other result	0	0	0	-34
Total operating revenue	0	0	391	-34
Balance as of June 30, 2015	3,027	18,213	1,781	-34

owners of the parent company

Revaluation reserves	Total shareholders' equity	Treasury shares at acquisition costs	Non-controlling interests	Total equity
0	21,530	-436	198	21,292
0	166	0	-52	114
0	21,696	-436	146	21,406
-122	22,508	-436	88	22,160
0	391	0	-29	362
0	-34	0	0	-34
0	357	0	-29	328
-122	22,865	-436	59	22,488

Condensed Consolidated Statement of Cash Flows

EUR k	Note	01/01- 06/30/2015	01/01- 06/30/2014
Cash flow from operating activities			
Earnings before taxes		604	320
Adjusted for:			
Amortization and depreciation		539	525
Other non-cash expenses/income		-165	21
Finance revenue		-61	-57
Finance costs		35	31
Working capital adjustments:			
+/- Receivables and other assets		798	393
+/- Inventories		11	-36
+/- Liabilities		-170	-725
+/- Provisions		-42	-24
+/- Deferred income		231	37
Interest paid		-35	-31
Income taxes paid		-253	2
Cash flow from operating activities		1,492	456
Cash flow from investing activities			
Purchase of intangible assets		-342	-154
Purchase of property, plant and equipment		-466	-85
Purchase of long term financial investments		-3,104	0
Interest received		20	9
Cash flow from investing activities		-3,892	-230
Cashflow from financing activities			
Cash received from investment grants		1	201
Changes in loans		760	-40
Cash flow from financing activities		761	161
Net change in cash and cash equivalents		-1,639	387
Cash and cash equivalents at the beginning of the reporting period		3,730	2,927
Changes of cash due to changes in the consolidation group		2	0
Cash and cash equivalents at the end of the reporting period (Liquid funds)	5	2,093	3,314

Notes on the Condensed Consolidated Interim Financial Statement

1. Company Information

The parent company, Vita 34 AG (the "Company"), with headquarters in Leipzig (Germany) Deutscher Platz 5a, listed in the commercial register of the District Court of Leipzig under HRB 20339, is a company whose corporate purpose is the storage, the production and the sale of stem cell and blood products for therapy and transplantation, the development, production and sale of medicinal products, as well as conducting projects in the field of biotechnology. Its subsidiaries (together with the Company referred to as the "Group") also operate in the field of cord blood storage.

The group interim financial statements for the period from January 1 until June 30, 2015 were approved for publication by the Management Board on July 23, 2015.

2. Accounting and Valuation Principles

2.1 Basis for the Preparation of the Financial Statements

The preparation of the group interim financial statements for the period from 1 January until June 30, 2015 has been conducted in accordance with IAS 34 "Interim Financial Reporting."

The condensed group interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the group financial statements as of December 31, 2014.

2.2 Changes in Accounting Policies

The accounting and valuation methods used to prepare the group interim financial statements correspond with the methods used in the preparation of the group financial statements for the fiscal year as of December 31, 2014.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2015:

- Annual improvements of the IFRS-cycle 2011-2013
- Modifications to IFRIC 21: Levies

The standards and interpretations required to be used for the first time starting 1 January 2015 resulted in no significant effects on the interim financial statements of Vita 34 AG.

3. Mergers

With a debt law contract dated December 1, 2014 VITA 34 Gesellschaft für Zelltransplantate m.b.H. Vienna, Austria ("Vita Austria"), a 100% subsidiary of Vita 34 AG acquired all of the required assets for business operations from the insolvent Vivocell Biosolutions GmbH & Co KG ("Vivocell") effective January 2, 2015. Vivocell had been up to that point the Austrian market leader for stem cell units from umbilical cord blood. Within the scope of the acquisition, approx. 13,000 stem cell units from umbilical cord blood were transferred to Vita Austria.

Due to the associated expansion of business operations at Vita Austria the company has been fully consolidated as of January 1, 2015. The applicable fair value of the assets and liabilities of Vita Austria at the time of first consolidation, as well as their book values directly prior to initial consolidation, are represented in the following table:

Overview of assets and debts of Vita Austria

EUR k	Applicable fair value at time of initial con- solidation	Value before initial consolida- tion
Assets	806	806
Non-current assets	78	78
Intangible assets	78	78
Current assets	728	728
Cash and cash equivalents	2	2
Trade receivables	710	710
Other receivables and assets	16	16
Debts	-783	-783
Current debts	-783	-783
Other debts	-781	-781
Provisions	-2	-2

The following asset values were used within the scope of the acquisition of the required assets for the business operations of Vivocell:

Overview of acquired assets from Vivocell

EUR k	Applicable fair value
Assets	
Transferred autologous storage contracts	506
Property, plant and equipment	238
Receivables from payment in instalments	111
Debt	
Passive deferred taxes	-51
Applicable fair value of transferred assets as of January 02, 2015	804

Based on the preliminary purchase price allocation, goodwill in the amount of EUR 154k resulted from the acquisition of the assets. This has been determined as follows:

EUR k	2015
Paid price for assets	650
minus applicable fair value for assets	-855
less passive deferred taxes	51
Goodwill	-154

The Vivocell lab in Graz was closed in 2015. The storage of the previous stem cell units as well as the expected new deposits will take place at Vita 34 AG in Germany. Thanks to the acquisition of the autologous stem cell units and the resulting, expected new stem cell units, positive effects are expected with regard to capacity utilization of the laboratory, as well as in the storage of stem cell units in Leipzig.

The applicable fair value of the assets, liabilities and contingent liabilities acquired were determined using observed market prices. If a market price could not be determined, income-oriented approaches of cost-oriented procedures for valuating the acquired assets and assumed liabilities were employed.

Assets from storage contracts taken over are posted under intangible assets, which were discounted down to the actual cash value using a depreciation rate. At the current time it cannot be determined to which extent the prior customers of Vivocell will agree to storage at Vita 34 AG. In determining future income, therefore, extensive discounts were made provisionally, in order to reflect the risk of termination of storage contracts by Vivocell customers.

The attainable amount from the contracts taken over was derived using an average storage duration of 25 years, the average cancellation rate determined from the company's prior year's values, based on the known current cost structures and Austrian tax rates.

The interest rate set for the cash flow prognosis was derived from a risk-free interest rate, taking into consideration a market risk premium at the time the assets were acquired.

The applicable fair value of the plant and equipment acquired was determined within the scope of an appraisal report prepared within the scope of the Vivocell insolvency proceedings.

The applicable fair value of the receivables acquired from installment payment agreements was determined taking the prior payment behavior of customers into consideration.

4. Consolidation Group

The consolidated interim financial statements encompass, apart from the parent company Vita 34 AG, the interim financial statements of the following subsidiaries:

- Novel Pharma, S.L., Madrid, Spain
- Secuvita S. L., Madrid, Spain
- stellacure GmbH, Leipzig, Germany
- VITA 34 Gesellschaft für Zelltransplantate m.b.H., Vienna, Austria

5. Cash and Cash Equivalents

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

Overview Cash and Cash Equivalents		
EUR k	06/30/2015	06/30/2014
Cash at banks and in hand	2,093	3,314
	2,093	3,314

6. Income Taxes

The significant components of the income tax expenditures listed in the condensed consolidated income statement consist of the following:

Consolidated statement of Income		
EUR k	01/01- 06/30/2015	01/01- 06/30/2014
Actual income taxes		
Actual income tax expense/income	24	-2
Deferred income tax		
On accrual and reversal of temporary differences	26	-26
On carryforwards	192	234
Income tax expense	242	206

7. Segment Reporting

The group is organized into business units according to products and services for the purpose of corporate taxation, and has the following two reporting business segments:

- The "Stem Cell Storage" business segment is active in the field of collection, processing and storage of stem cells from umbilical cord blood, as well as umbilical cord tissue, in addition to the development of cell therapy procedures.
- The "Biotechnology" business segment develops biological processes for cell and tissue culture and employs them in the optimization and multiplication of cells and plants. Analyses and services are performed for environmental projects.

The operating profit/loss of the business units is monitored by management separately, in order to make decisions concerning the distribution of resources and to determine the profitability of the units. The development of the segments is evaluated using operating profit. The group financing (including finance income of EUR 61k and finance expense of EUR 35k) as well as taxes on income and profits, are taxed uniformly across the group and are not attributed to the individual segments.

The offset prices between the operative segments are determined in accordance with typical market conditions amongst unrelated third-parties.

The following table contains information on income and segment results of the operating segments of the Group for the period from January 1 to June 30, 2015 and 2014:

Period from 01/01/-06/30/2015

EUR k	Stem Cell Storage	Bio-technology	Total	Consolidated	Group
Revenue from transactions with external customers	6,236	182	6,418	0	6,418
EBITDA (earnings before interest and taxes, depreciation and amortization)	961	156	1,117	0	1,117
Depreciation	465	74	539	0	539
EBIT (operating profit)	496	82	578	0	578
Segment assets	35,448	3,930	39,378	-1,109	38,269
Segment liabilities	-14,879	-2,011	-16,890	1,109	-15,781

Period from 01/01/-06/30/2014

EUR k	Stem Cell Storage	Bio-technology	Total	Consolidated	Group
Revenue from transactions with external customers	5,826	264	6,090	0	6,090
EBITDA (earnings before interest and taxes, depreciation and amortization)	480	339	819	0	819
Depreciation	463	62	525	0	525
EBIT (operating profit)	17	277	294	0	294
Segment assets	32,361	3,011	35,372	0	35,372
Segment liabilities	-13,527	-439	-13,966	0	-13,966

7.1 Information Concerning Geographic Regions

The geographic segments of the group are determined in accordance with the revenues earned in the geographical areas.

The following table contains information on sales revenues and segment results of the geographic segments of the group for the period from January 1 to June 30, 2015 and 2014:

Period from 01/01/-06/30/2015

EUR k	DACH	Spain	Total	Consolidated	Group
Revenue from transactions with external customers	5,092	1,326	6,418	0	6,418
Revenue from transactions with other segments	346	0	346	-346	0
	5,438	1,326	6,764	-346	6,418
EBITDA (earnings before interest and taxes, depreciation and amortization)	1,169	-52	1,117	0	1,117
Depreciation	389	150	539	0	539
EBIT (operating profit)	780	-202	578	0	578
Segment assets	33,911	7,721	41,632	-3,363	38,269
Segment liabilities	-12,217	-6,927	-19,144	3,363	-15,781

Period from 01/01/-06/30/2014

EUR k	DACH	Spain	Total	Consoli- dated	Group
Revenue from transactions with external customers	4,723	1,367	6,090	0	6,090
Revenue from transactions with other segments	253	0	253	-253	0
	4,976	1,367	6,343	-253	6,090
EBITDA (earnings before interest and taxes, depreciation and amortization)	860	-41	819	0	819
Depreciation	319	206	525	0	525
EBIT (operating profit)	541	-247	294	0	294
Segment assets	30,755	7,942	38,697	-3,325	35,372
Segment liabilities	-10,661	-6,630	-17,291	3,325	-13,966

DACH: Germany, Austria, Switzerland (DACH)

8. Information on related party transactions

The following table contains consolidated subsidiaries in the period from January 1 to June 30, 2015 and 2014:

Overview of subsidiaries involved in consolidation

%	2015	2014
Novel Pharma, S.L., Madrid, Spain	100.0	100.0
Secuvita S.L., Madrid, Spain	88.0	88.0
stellacure GmbH, Leipzig, Germany	75.2	75.2
VITA 34 Gesellschaft für Zelltransplantate m.b.H., Vienna, Austria	100.0	100.0

Associated companies and persons include subsidiaries not involved in the Group financial statements, shareholders with significant influence and persons in key positions within the company.

The following table provides the total amount of transactions, which have been entered into with related parties in the period from January 1 to June 30, 2015 and 2014:

Granted to loans to affiliated companies

EUR k	Received interest	Receivables
Subsidiaries of Vita 34 AG		
VITA 34 Slovakia, s.r.o.		
01/01/-06/30/2015	2	229
01/01/-06/30/2014	0	32

A working capital credit line in the amount of EUR 300k was granted to VITA 34 Slovakia, s.r.o. The working capital credit line is not secured and has an open term. The interest rate is 200 basis points over the Euro Interbank Offered Rate and is adjusted annually.

The following table provides the total amount of remuneration persons in key positions in the period from January 1 to June 30, 2015 and 2014:

Expenses to related parties and key management personnel

EUR k	01/01 – 06/30/2015	01/01 – 06/30/2014
There is an agreement with a former member of the management board concerning rights of use and sale relating to a patent application and two patents. The former management board member has surrendered the patents concerned and patent application permanently for use by Vita 34 AG.		
No compensation was paid for the surrender for use in fiscal year 2014 and 2015.		
Compensation of key management personnel of the Group:		
Short-term benefits:		
Remuneration of the supervisory board	45	14
Management board salaries	264	171

The Group obligated itself to render a performance in the amount of EUR 195k for a company that is close to a member of the Supervisory Board. In the period from January 1 to June 30, 2015 the cost to the group was EUR 26k.

In the period from January 1 to June 30, 2015 a GmbH [German limited liability company] with close ties to a Supervisory Board member, provided services to the Group. The costs to the Group for services rendered was EUR 1k.

Dr. Gerth (CEO), was paid rent for the use of storage rooms in the period from January 1 to June 30, 2015 in the amount of EUR 5k (period from January 1 to June 30, 2014: EUR 5k).

Leipzig, 23 July 2015

The Vita 34 AG Management Board



Dr. André Gerth
CEO



Jörg Ulbrich
CFO

Declaration of the Legal Representatives

We hereby affirm that to the best of our knowledge the consolidated financial statements provide a picture of the asset, financial and profit situation of the Group, which reflects the actual circumstances in accordance with the applicable accounting policies, and that the management report presents the course of business, including the financial results, and the situation of the Company in a manner that corresponds with the actual circumstances, and that the most important opportunities and risks of the foreseeable development of the Group have been described.

Leipzig, July 2015

Management Board of Vita 34 AG

The image shows two handwritten signatures in black ink. The signature on the left is 'Dr. Gerth' and the signature on the right is 'J. Ulbrich'. Both are written in a cursive, flowing style.

Dr. André Gerth
CEO

Jörg Ulbrich
CFO

Contact Information

Contact

Vita 34 AG
Deutscher Platz 5
04103 Leipzig
Germany

Telephone: +49 341 48792-40
Fax: +49 341 48792-39
E-Mail: ir@vita34group.de

Copy and Editing

Vita 34 AG, Leipzig
cometis AG, Wiesbaden

Photo credits

Cover: shutterstock.de – 37995709

Production

The production of the paper is certified in accordance with DIN ISO 9001 and 14001. The cellulose and paper plants of the manufacturer are certified in accordance with FSC Chain of Custody. The wood originated exclusively from controlled and sustainably managed forests.

Publication

This Interim Report was published in German and English on 23 July 2015 and is available for download on our internet site.

Vita 34 on the Internet: www.vita34group.com

Vita 34 AG

Registered office: Deutscher Platz 5 | 04103 Leipzig, Germany

Mailing address: Perlickstraße 5 | 04103 Leipzig, Germany

Telephone +49 (0) 341 487 92 40 | Telefax +49 (0) 341 487 92 39

E-Mail ir@vita34group.de | www.vita34group.com | www.facebook.com/vita34